JCP
DOVA

Jabre Capital Partners’s Dova Pharmaceuticals, Inc. Common Stock DOVA Stock Holding History

Jabre Capital Partners’s Portfolio DOVA Stock Details DOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-43,232
Closed -$907K – 123
2018
Q3 		$907K Buy
43,232
+30,232
+233% +$720K 0.3% 65
2018
Q2 		$389K Sell
13,000
-4,465
-26% -$122K 0.03% 135
2018
Q1 		$474K Buy
+17,465
New +$523K 0.1% 114

Other funds holding DOVA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FI
Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jabre Capital Partners's DOVA Position: Q4 2018 in Review

Jabre Capital Partners sold out of Dova Pharmaceuticals, Inc. Common Stock (DOVA) in Q4 2018, closing a stake of 43,232 shares — an estimated $907K sold.

Jabre Capital Partners first reported a position in DOVA in Q1 2018 and held it in 3 quarters. The position peaked at $907K in Q3 2018. 58 funds tracked by Wall St. Rank hold DOVA as of Q4 2018.

  • Jabre Capital Partners reported no remaining Dova Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Jabre Capital Partners sold 43,232 Dova Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $907K.
  • Jabre Capital Partners first reported a position in Dova Pharmaceuticals, Inc. Common Stock in Q1 2018 and held it in 3 quarters.
  • Jabre Capital Partners's Dova Pharmaceuticals, Inc. Common Stock position peaked at $907K in Q3 2018.
  • 58 funds tracked by Wall St. Rank held Dova Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Jabre Capital Partners's 13F filing for Q4 2018, filed 14 Feb 2019.